Paul Jackson
Chief Operating Officer Adcytherix
Seminars
Tuesday 9th March 2027
Next-Generation ADCs: Advancing Targeted Cancer Therapy
2:45 pm
- Developing next-generation ADCs designed to overcome resistance to current ADC therapies
- Leveraging innovative payloads and advanced conjugation strategies to enhance efficacy and expand the therapeutic window
- Translating novel ADC technologies into differentiated therapies for patients with high unmet need
